Aprea reports Q2 2026 results, faster enrollment in APR-1051 trial

Aprea Therapeutics reported financial results for the second quarter ended June 30, 2026, on August 12, 2026, saying the number of active clinical sites for its ACESOT-1051 trial is expanding from three to ten, ahead of an anticipated clinical catalyst¹. The company said it expects enrollment to reach 6 to 10 patients per month by the fourth quarter of 2026, which could speed up the pace of clinical data generation¹.

The trial is testing APR-1051, described by the company as a potent and selective, oral small molecule WEE1 inhibitor designed to potentially address therapeutic window limitations observed with earlier WEE1 programs¹. Using proceeds from a private placement, Aprea is expanding the study to enroll a minimum of 50 patients with either uterine serous carcinoma or cyclin E-overexpressing, platinum-resistant ovarian cancer¹, with dose escalation and backfill expansion expected to be complete in the second quarter of 2027¹.

Aprea also plans combination studies, pairing APR-1051 with immune checkpoint therapy in HPV-positive head and neck squamous cell carcinoma¹ and with standard-of-care chemotherapy in colorectal cancer¹.

On the ATR inhibitor program, Aprea said in 2025 it determined a recommended Phase 2 dose of 1,100 mg once daily for ATRN-119 and then closed the ABOYA-119 study to focus resources on APR-1051¹.

Financially, the company reported cash and cash equivalents of $41.2 million as of June 30, 2026, up from $14.6 million at the end of 2025¹, and said this should be sufficient to fund operations into the first quarter of 2028¹. Quarterly operating loss was $4.0 million, versus $3.4 million in the same quarter of 2025¹, with net loss of $3.6 million, or $(0.07) per basic share, on about 53.5 million weighted-average shares outstanding¹.